Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Secondary analyses in the pivotal trials of Acorda’s Ampyra (dalfampridine) were of front-line interest to FDA as the agency grappled with the first indication for improving walking ability in multiple sclerosis patients and an untested primary endpoint.
You may also be interested in...
A Cautious Guide To The Interpretation Of Clinical Trials From NEJM
Determining the success or failure of a randomized trial requires looking beyond the p-value for the primary endpoint, review articles in The New England Journal of Medicine urge.
Efficacy Endpoint For BioMarin’s Vimizim Faces FDA Panel Scrutiny
Review documents released ahead of a Nov. 19 advisory committee meeting question whether the six-minute walk test is an appropriate endpoint for the Morquio A syndrome treatment, and whether the findings are clinically meaningful.
Ampyra Trial Failure Is Not All Bad News For Acorda
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.